Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Basit Öğe Kaydı
dc.authoridKaraoglan, Beliz Bahar/0000-0002-5021-7588
dc.authoridAkyildiz, Arif/0000-0002-4452-2076
dc.authoridDemirci, Nebi Serkan/0000-0001-5943-889X
dc.authoridGuliyev, Murad/0000-0002-2981-8098
dc.authoridKoksal, Baris/0000-0002-0418-5749
dc.contributor.authorAkyildiz, Arif
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorKoksal, Baris
dc.contributor.authorKaraoglan, Beliz Bahar
dc.contributor.authorKivrak, Derya
dc.contributor.authorIsmayilov, Rashad
dc.contributor.authorAslan, Firat
dc.date.accessioned2024-08-31T07:50:57Z
dc.date.available2024-08-31T07:50:57Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial. This study aimed to evaluate the real-world outcomes of nivolumab in patients with non-nasopharyngeal HNC. Design In this multicenter retrospective study, we analyzed 124 patients with recurrent or metastatic non-nasopharyngeal HNC who received nivolumab in the second-line setting and beyond. Data were collected from 20 different cancer centers across Turkey. The effectiveness and safety of the treatment and survival outcomes were evaluated. Results Nivolumab exhibited favorable clinical responses, yielding an objective response rate of 29.9% and a disease control rate of 55.7%. Safety assessments revealed a generally well-tolerated profile, with no instances of treatment discontinuation or mortality due to side effects. Survival analysis disclosed a median overall survival (OS) of 11.8 (95% CI 8.4-15.2) months. Multivariate analysis revealed that ECOG-PS >= 1 (HR: 1.64, p = 0.045), laryngeal location (HR: 0.531, p = 0.024), and neutrophil-to-lymphocyte ratio > 3.5 (HR: 1.97, p = 0.007) were independent predictors of OS. Conclusions Nivolumab is an effective and safe treatment option for patients with recurrent or metastatic non-nasopharyngeal HNC in real-world settings. Further studies are needed on factors affecting response to treatment and survival outcomes.en_US
dc.description.sponsorshipHacettepe Universityen_US
dc.description.sponsorshipNo Statement Availableen_US
dc.identifier.doi10.1007/s00405-024-08744-4
dc.identifier.issn0937-4477
dc.identifier.issn1434-4726
dc.identifier.pmid38795147en_US
dc.identifier.scopus2-s2.0-85194398073en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1007/s00405-024-08744-4
dc.identifier.urihttps://hdl.handle.net/11454/105441
dc.identifier.wosWOS:001234603400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Archives of Oto-Rhino-Laryngologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectHead And Neck Canceren_US
dc.subjectNivolumaben_US
dc.titleReal-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu